Central nervous system (CNS) tumors remain the deadliest cancers in children, underscoring the need for innovative therapies. These tumors widely express tumor-associated antigens (TAAs) such as WT1, PRAME, and survivin. Researchers developed autologous, nongenetically engineered trivalent T cells targeting these three TAAs.
In a phase 1 trial, they evaluated the safety, feasibility, and preliminary efficacy of these T cells in children with newly diagnosed diffuse intrinsic pontine glioma without lymphodepletion (arm A, n = 11), and relapsed or recurrent nonbrainstem CNS malignancies without (arm B, n = 18) or with (arm C, n = 4) lymphodepletion. Patients in arm A achieved a median overall survival of 13.7 months from diagnosis (range 6.2 to 32.0 months), while patients in arms B and C had a median progression-free survival of 5.0 months from infusion (range 0.5 to 51.6 months).…
